Description: OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail. The company was founded in 2000 and is headquartered in Yardley, Pennsylvania.
Home Page: www.optinose.com
1020 Stony Hill Road
Yardley,
PA
19067
United States
Phone:
267 364 3500
Officers
| Name | Title |
|---|---|
| Dr. Ramy A. Mahmoud M.D., M.P.H. | CEO & Director |
| Mr. Michael F. Marino Esq. | Chief Legal Officer & Corporate Secretary |
| Mr. Paul Spence | Chief Commercial Officer |
| Mr. P. Terence Kohler | Chief Financial Officer |
| Mr. Anthony J. Krick | VP of Finance & Chief Accounting Officer |
| Mr. Jonathan Neely | Vice President of Investor Relations & Business Development |
| Ms. Karen E. Brophy | Chief Human Resources Officer & VP of Human Resources |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 23.8844 |
| Price-to-Sales TTM: | 0.9481 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 132 |